

Resource Summary Report

Generated by [dkNET](#) on Aug 3, 2026

Hu CD8 BUV805 RPA-T8 50ug

RRID:AB_2873737

Type: Antibody

Proper Citation

BD Biosciences Cat# 749366, RRID:AB_2873737

Antibody Information

URL: http://antibodyregistry.org/AB_2873737

Proper Citation: BD Biosciences Cat# 749366, RRID:AB_2873737

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Hu CD8 BUV805 RPA-T8 50ug

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: RPA-T8

Antibody ID: AB_2873737

Vendor: BD Biosciences

Catalog Number: 749366

Record Creation Time: 20250819T214014+0000

Record Last Update: 20250819T234300+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD8 BUV805 RPA-T8 50ug.

No alerts have been found for Hu CD8 BUV805 RPA-T8 50ug.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Schulenberg S, et al. (2025) Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial. *iScience*, 28(11), 113680.

Lam N, et al. (2025) Asynchronous aging and turnover of human circulating and tissue-resident memory T cells across sites. *Immunity*, 58(9), 2271.

Davis-Porada J, et al. (2024) Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues. *Immunity*, 57(12), 2895.

Stavarakaki E, et al. (2024) An autologous ex vivo model for exploring patient-specific responses to viro-immunotherapy in glioblastoma. *Cell reports methods*, 4(3), 100716.

Potts M, et al. (2023) Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity. *Cell reports*, 42(6), 112613.

Gubser C, et al. (2023) GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy. *iScience*, 26(11), 108165.

Ducoin K, et al. (2022) Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. *Oncoimmunology*, 11(1), 2046931.